<DOC>
	<DOCNO>NCT00390858</DOCNO>
	<brief_summary>In 4-year extension study safety , efficacy pharmacokinetics deferasirox regularly transfuse pediatric patient β-thalassemia major assess . Patients successfully complete main 1 year trial ( NCT00390858 ) eligible continue extension trial receive chelation therapy deferasirox 4 year .</brief_summary>
	<brief_title>A 4-year Extension Study Core 1-year Study Iron Chelation Therapy With Deferasirox β-thalassemia Major Pediatric Patients With Transfusional Iron Overload .</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Completion plan 12month core trial , ( NCT00390858 ) . Female patient reach menarche sexually active use doublebarrier contraception , oral contraceptive plus barrier contraceptive , must undergo clinically document total hysterectomy and/or ovariectomy , tubal ligation . Written inform consent obtain patient , and/or parent legal guardian accordance national legislation . Pregnant breast feeding patient Patients history noncompliance medical regimen patient consider investigator potentially unreliable . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>β-thalassemia major</keyword>
	<keyword>iron overload</keyword>
	<keyword>deferasirox</keyword>
	<keyword>pediatric rare anemia</keyword>
</DOC>